Bria-Pros+ is based on BriaCell’s next generation personalized immunotherapy platformBria-Pros+ is capable of activating multiple types of immune cells,.
04.01.2024 - WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) - Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of novel, conditionally activated INDUKINE therapeutics .
Mendus AB , a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced its participation in the following upcoming investor and industry conferences: LSX.
Third dose cohort initiated in Phase 1 trial of PYX-201, Pyxis Oncology s first ADC product candidate Preliminary data from two Phase 1 trials on track for late 2023 to early 2024 Apexigen. -August 11, 2023 at 07:01 am- MarketScreener
Pyxis Oncology Reports Financial Results for Second-Quarter 2023 and Provides Corporate Update eagletribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eagletribune.com Daily Mail and Mail on Sunday newspapers.